Adiponectin in health and disease

Oh, Deborah K.; Ciaraldi, Theodore P.; Henry, Robert R.

doi:10.1111/j.1463-1326.2006.00610.x

Cited by 249 publications

(191 citation statements)

References 79 publications

Supporting

Mentioning

177

Contrasting

Unclassified

Order By: Relevance

“…Last, up-regulation of adiponectin receptors and the use of adiponectin receptor agonists may also prove to be of clinical value in the future. 38 prospects Adiponectin is a target for future research to reduce morbidity and mortality from atherosclerotic disease.…”

Section: Obesity and Adiponectinmentioning

confidence: 99%

Relationship between adiponectin, obesity and insulin resistance

Balsan¹,

Vieira²,

Oliveira³

et al. 2015

Rev. Assoc. Med. Bras.

144

100

View full text Add to dashboard Cite

Conflict of interest: noneObjectives: the conditions of obesity and overweight pose a major risk for a number of comorbidities, including clinical syndromes resulting from atherosclerotic disease. Recent studies strongly indicate that adipose tissue is an active endocrine organ that secretes bioactive factors such as adipokines. Adiponectin appears to have a regulatory role in the mechanism of insulin resistance and in the development of atherosclerosis. This systematic review aims to evaluate the anti-atherogenic effects of adiponectin and its properties to improve and mimic metabolic and vascular actions of insulin and its influence on endothelial function. Methods: a qualitative, exploratory and literature review was performed in the PubMed, Portal Capes and Scielo databases using as key-words "adiponectin", "obesity", "insulin resistance", "anti-inflammatory", "therapeutic strategies" and "future prospects". Results: evidence suggests that adiponectin has anti-atherogenic properties with anti-inflammatory effects on the vascular wall. Moreover, it modifies the vascular intracellular signaling and has indirect antioxidant effects on the human myocardium. On the other hand, there are studies suggesting that increased levels of adiponectin are paradoxically associated with a worse prognosis in heart failure syndrome, although the mechanisms are not clear. Conclusion: it is not clear whether adiponectin levels have any clinical significance for risk stratification in cardiovascular disease or if they simply reflect the activation of complex underlying mechanisms. Changes in lifestyle and some drug treatments for hypertension and coronary heart disease have shown significant effect to increase adiponectin levels, and simultaneously decrease in insulin resistance and endothelial dysfunction.

show abstract

Section: Obesity and Adiponectinmentioning

confidence: 99%

Relationship between adiponectin, obesity and insulin resistance

Balsan¹,

Vieira²,

Oliveira³

et al. 2015

Rev. Assoc. Med. Bras.

144

100

View full text Add to dashboard Cite

show abstract

“…Ainsi, l'effet de la vitamine E sur l'adipogenese a ete recemment evalue, il apparaît que les differents vitameres n'ont pas les mêmes effets sur differenciation adipo- (Rosen et Spiegelman, 2006 ;LaraCastro et al, 2007 ;Oh et al, 2007). Elle augmente aussi l'oxydation lipidique et supprime la neoglucogenese, le captage des acides gras et la lipogenese au niveau hepatique.…”

Section: Effets De La Vitamine E Sur La Biologie Du Tissu Adipeuxunclassified

Vitamine E et physiologie du tissu adipeux

Landrier

2011

OCL

View full text Add to dashboard Cite

“…Adiponectin also affects lipases, foam cell process and atherosclerosis to increase insulin sensitivity, decrease visceral fat, reduce triglycerides and increase high-density lipoprotein levels. [24][25][26] Adiponectin is anti-inflammatory and protects the vasculature against atherosclerosis. Obesity reduces the expression and levels of adiponectin.…”

Section: -17mentioning

confidence: 99%

Obesity, low testosterone levels and erectile dysfunction

et al. 2008

View full text Add to dashboard Cite

Obesity is an important risk factor for many common diseases including cardiovascular disease (CVD), type 2 diabetes, cancer and erectile dysfunction (ED). Adipose tissues produce a number of adipokines and cytokines, which affect endothelial and metabolic function resulting in insulin resistance and the metabolic syndrome (risks factors for CVD). Both ED and metabolic syndrome improve with a reduction in body mass index (BMI). The relationships among obesity, metabolic syndrome, ED, sex hormonebinding globulin (SHBG) and serum total and free testosterone levels are complex and often confusing to the physician. It is known that BMI is inversely proportional to serum total testosterone concentrations; low serum SHBG levels in obesity contribute to the low serum total testosterone. Recent studies show that BMI is also inversely proportional to free testosterone concentration. The characteristic low serum testosterone concentrations observed in obese men are also present in men with the metabolic syndrome and type 2 diabetes mellitus. A small proportion of men with ED have hypogonadism; however, the proportion increases if these men are obese with manifestations of the metabolic syndrome or type 2 diabetes mellitus. ED is a common symptom in patients with type 2 diabetes who also have low testosterone levels. This review describes the relationships between low serum testosterone concentrations and ED in obese patients and those with metabolic syndrome and type 2 diabetes mellitus.

show abstract

Adiponectin in health and disease

Cited by 249 publications

References 79 publications

Relationship between adiponectin, obesity and insulin resistance

Relationship between adiponectin, obesity and insulin resistance

Vitamine E et physiologie du tissu adipeux

Obesity, low testosterone levels and erectile dysfunction

Contact Info

Product

Resources

About